13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q1 2024. See the latest, Q2 2026 →
Reported value
$2.51B
+17% on the quarter before
Positions
43
1 new · 2 sold out
Top 10
89.4%
of the value
Est. gain
+$131.6M
on stocks held all quarter
Est. return
+7.4%
on those stocks since Q4 2023
Positions as of Mar 31, 2024, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2023. Striped tiles are options.
Largest buys
Since Q4 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Gitlab Inc~$414.7MAdded · 7.7% → 22.6%+7,111,021 shares
- Freshworks Inc~$151.2MAdded · 4.4% → 8.9%+8,301,048 shares
- Prime Medicine Inc~$22.4MAdded · 4.9% → 4.2%+3,200,000 shares
- Fractyl Health Inc~$4.9MNew · 0.0% → 0.2%+662,584 shares
Largest sells
Since Q4 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Dexcom Inc~$262.3MCut · 21.2% → 9.9%−1,891,112 shares
- CrowdStrike~$137.2MCut · 15.2% → 10.9%−427,894 shares
- Oscar Health Inc~$17.1MCut · 0.7% → 0.3%−1,147,099 shares
- Neumora Therapeutics Inc.~$6.9MSold out · 0.3% → 0.0%−404,732 shares
- Invivyd Inc~$5.1MCut · 1.0% → 0.8%−1,153,663 shares
- Vera Therapeutics Inc~$2.6MCut · 0.2% → 0.4%−60,316 shares
- Science 37 Holdings Inc~$856,343Sold out · 0.0% → 0.0%−160,364 shares
Holdings
As of Mar 31, 2024. Changes are in shares against Dec 31, 2023, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gitlab IncCLASS A COM · shares +269% · price −7.4% | 22.6% | $569.1M | −$12.3M | ||||||||
| CrowdStrikeCL A · shares −33% · price +25.6% | 10.9% | $274.4M | +$55.9M | ||||||||
| Dexcom IncCOM · shares −51% · price +11.8% | 9.9% | $248.4M | +$26.2M | ||||||||
| Arm Holdings PlcSPONSORED ADR · shares 0% · price +66.3% | 9.7% | $245.1M | +$97.7M | ||||||||
| Freshworks IncCLASS A COM · shares +206% · price −22.5% | 8.9% | $224.7M | −$21.3M | ||||||||
| Revolution Medicines IncCOM · shares 0% · price +12.4% | 6.8% | $170.9M | +$18.8M | ||||||||
| Verve Therapeutics IncCOM · shares 0% · price −4.7% | 6.5% | $164.0M | −$8.2M | ||||||||
| UiPathCL A · shares 0% · price −8.7% | 6.3% | $159.5M | −$15.3M | ||||||||
| Prime Medicine IncCOM · shares +27% · price −21.0% | 4.2% | $105.4M | −$22.1M | ||||||||
| SnowflakeCL A · shares 0% · price −18.8% | 3.4% | $86.6M | −$20.0M | ||||||||
| Planet Labs PbcCOM CL A · shares 0% · price +3.2% | 3.2% | $81.5M | +$2.6M | ||||||||
| Sana Biotechnology IncCOM · shares 0% · price +145.1% | 1.1% | $28.1M | +$16.6M | ||||||||
| Invivyd IncCOM · shares −20% · price +12.7% | 0.80% | $20.1M | +$2.3M | ||||||||
| Lyell Immunopharma IncCOM · shares 0% · price +14.9% | 0.52% | $13.1M | +$1.7M | ||||||||
| Relay Therapeutics IncCOM · shares 0% · price −24.6% | 0.52% | $13.0M | −$4.3M | ||||||||
| Beam Therapeutics IncCOM · shares 0% · price +21.4% | 0.42% | $10.6M | +$1.9M | ||||||||
| Vera Therapeutics IncCL A · shares −20% · price +180.4% | 0.41% | $10.4M | +$6.7M | ||||||||
| Monte Rosa Therapeutics IncCOM · shares 0% · price +24.8% | 0.41% | $10.3M | +$2.0M | ||||||||
| Desktop Metal IncCOM CL A · shares 0% · price +17.3% | 0.39% | $9.7M | +$1.4M | ||||||||
| Tscan Therapeutics IncCOM · shares 0% · price +36.2% | 0.34% | $8.6M | +$2.3M | ||||||||
| Illumina IncCOM · shares 0% · price −1.4% | 0.29% | $7.3M | −$102,662 | ||||||||
| Oscar Health IncCL A · shares −70% · price +62.5% | 0.29% | $7.2M | +$2.8M | ||||||||
| Dianthus Therapeutics IncCOM · shares 0% · price +188.5% | 0.25% | $6.3M | +$4.1M | ||||||||
| Fractyl Health IncCOM · shares New | 0.20% | $4.9M | — | ||||||||
| Rapt Therapeutics IncCOM · shares 0% · price −63.9% | 0.19% | $4.9M | −$8.6M | ||||||||
| Total · 43 positions | 100% | $2.51B | +$131.6M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2023 to Q1 2024: 41 stocks held throughout, up $131.6M (+7.4%).
- Arm Holdings Plc+$97.7M+66%
- CrowdStrike+$55.9M+26%
- Dexcom Inc+$26.2M+12%
- Revolution Medicines Inc+$18.8M+12%
- Sana Biotechnology Inc+$16.6M+145%
- Gitlab Inc−$12.3M−7%
- UiPath−$15.3M−9%
- Snowflake−$20.0M−19%
- Freshworks Inc−$21.3M−22%
- Prime Medicine Inc−$22.1M−21%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |